Trial Profile
A retrospective study to evaluate whether prolonged administration of bevacizumab leads to brain atrophy in patients with high-grade gliomas.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- 26 Feb 2016 New trial record